CClinicalTrials.gg
CompletedNCT02873481CPC+YUpdated Jun 6, 2018Results posted

Centering Pregnancy Care + Yoga for Diverse Pregnant Women

An interventional study of Centering Pregnancy Care plus Yoga (CPC+Y) in Pregnancy, sponsored by Virginia Commonwealth University. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

This is a pilot longitudinal mixed-methods study of pregnant women (n=20) who participate in CPC+Y at the VCU Health System Nelson Clinic or the Virginia Department of Health Richmond Health District's prenatal clinic (RHD) during their pregnancies. This pilot project will provide the necessary preliminary data to fuel an appropriately powered randomized controlled trial to evaluate the effects of CPC+Y in controlling weight gain, enhancing stress resilience, and improving maternal-child outcomes among overweight/obese diverse women. Because increasing physical activity has been found to have important mental health effects and maternal-child outcomes, it stands to reason that this innovative intervention has the potential to impact the way prenatal care is delivered in high risk populations.

02

Conditions studied

  • Pregnancy
03

In context

Lead sponsor

Virginia Commonwealth University is the lead sponsor of 641 studies on the registry; 82 are open to participants now.

Of its 88 completed or terminated interventional studies of FDA-regulated products, 62 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • pregnant women age 18 years or older
  • currently participating in CPC at the VCU Health System Nelson Clinic or Richmond Health District

Exclusion criteria

Exclusion Criteria:

  • current physical conditions preventing participation in physical activity (ACOG guidelines: restrictive lung disease, hemodynamically significant heart disease, incompetent cervix, multiple gestation at risk of premature labor, persistent 2nd or 3rd trimester bleeding, placenta previa after 26 weeks gestation, premature labor, ruptured membranes, preeclampsia, severe anemia)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Yoga (CPC+Y)

    Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)

    Behavioral: Centering Pregnancy Care plus Yoga (CPC+Y)

  • No intervention
    Comparison (CPC alone)

    To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.

Interventions

  • BehavioralCentering Pregnancy Care plus Yoga (CPC+Y)

    Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session

06

What researchers measure

Primary outcomes

  1. Feasibility of Retention/ Adherence

    Numbers of women who stayed in the study through their pregnancy and attended all intervention sessions

    Time frame: through study completion, an average of 20 weeks

Secondary outcomes

  1. Self-efficacy for Physical Activity

    Physical Activity Self-Efficacy Scale (PASES): The Physical Activity Self-Efficacy Scale (PASES) is an 8 question scale which contains items about SM of physical activities and social support regarding PA. This psychometrically sound scale was selected because of its specific focus on SM of PA. Originally designed for adolescents, the wording has been slightly adapted for an adult sample. A higher score indicates higher levels of self-efficacy. Lowest possible score is 8; highest possible score is 40. Only participants in the intervention arm receive this particular instrument.

    Time frame: baseline (early pregnancy), end of pregnancy (approx 10 months)

  2. Salivary Biomarkers (α-amylase)

    salivary biomaker measure. This is an exploratory measure related to acute stress, yet it does not currently have known clinical associations with certain numeric levels of this measure (i.e., there is no identified "high" or "low" level of alpha-amylase). Only collected in the intervention group.

    Time frame: baseline (early pregnancy), mid-pregnancy (approx 4-5 months), end of pregnancy (approx 10 months)

  3. Depressive Symptoms

    Patient Health Questionnaire-9 (PHQ9): The PHQ-9 includes self-report items regarding depressive symptoms over the past two weeks. Total scores range from 0-27, where 0-4 indicates minimal depression, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, and ≥20 severe depressive symptoms.

    Time frame: baseline (early pregnancy), end of pregnancy (approx 10 months)

  4. Stress

    Perceived Stress Scale (PSS): The Perceived Stress Scale-10 (PSS-10), a widely used, psychometrically sound instrument, will assess the degree to which a participant perceives stress in her life during the past month. The PSS-10 asks respondents to report about feelings such as unpredictability, uncontrollability, and overloading of stress in their lives; scores range from 0-40; higher scores correspond to a higher perceived stress level.

    Time frame: baseline (early pregnancy), end of pregnancy (approx 10 months)

  5. Number of Subjects Participating in Focus Group

    Women will volunteer to discuss their experiences (acceptability) with the intervention through focus groups conducted following the intervention period

    Time frame: at intervention completion, an average of 20 weeks

  6. Recruitment Feasibility

    Numbers of women who agreed to participate in the study;

    Time frame: at intervention completion, an average of 20 weeks

07

Results

Posted Jun 6, 2018

Participant flow

Participant flow — Overall Study
MilestoneYoga (CPC+Y)Comparison (CPC Alone)
Started1517
Completed1517
Not completed00

Outcome measures

PrimaryFeasibility of Retention/ Adherence

Numbers of women who stayed in the study through their pregnancy and attended all intervention sessions

Time frame:
through study completion, an average of 20 weeks
Reported as:
Count of participants · Participants
Feasibility of Retention/ Adherence
ParticipantsYoga (CPC+Y)Comparison (CPC Alone)
Feasibility of Retention/ Adherence1517
SecondarySelf-efficacy for Physical Activity

Physical Activity Self-Efficacy Scale (PASES): The Physical Activity Self-Efficacy Scale (PASES) is an 8 question scale which contains items about SM of physical activities and social support regarding PA. This psychometrically sound scale was selected because of its specific focus on SM of PA. Originally designed for adolescents, the wording has been slightly adapted for an adult sample. A higher score indicates higher levels of self-efficacy. Lowest possible score is 8; highest possible score is 40. Only participants in the intervention arm receive this particular instrument.

Time frame:
baseline (early pregnancy), end of pregnancy (approx 10 months)
Reported as:
Mean · units on a scale
Self-efficacy for Physical Activity
units on a scaleYoga (CPC+Y)
Baseline25.8 ± 4.8
End of pregnancy25 ± 3.4
SecondarySalivary Biomarkers (α-amylase)

salivary biomaker measure. This is an exploratory measure related to acute stress, yet it does not currently have known clinical associations with certain numeric levels of this measure (i.e., there is no identified "high" or "low" level of alpha-amylase). Only collected in the intervention group.

Time frame:
baseline (early pregnancy), mid-pregnancy (approx 4-5 months), end of pregnancy (approx 10 months)
Reported as:
Mean · U/mL
Salivary Biomarkers (α-amylase)
U/mLYoga (CPC+Y)
Baseline112.4145 ± 95.886
Mid-pregnancy99.59 ± 84.888
End of pregnancy127.045 ± 54.539
SecondaryDepressive Symptoms

Patient Health Questionnaire-9 (PHQ9): The PHQ-9 includes self-report items regarding depressive symptoms over the past two weeks. Total scores range from 0-27, where 0-4 indicates minimal depression, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, and ≥20 severe depressive symptoms.

Time frame:
baseline (early pregnancy), end of pregnancy (approx 10 months)
Reported as:
Mean · units on a scale
Depressive Symptoms
units on a scaleYoga (CPC+Y)Comparison (CPC Alone)
Baseline5.2 ± 4.86.9 ± 5.3
End of pregnancy6.3 ± 5.912 ± 4.1
SecondaryStress

Perceived Stress Scale (PSS): The Perceived Stress Scale-10 (PSS-10), a widely used, psychometrically sound instrument, will assess the degree to which a participant perceives stress in her life during the past month. The PSS-10 asks respondents to report about feelings such as unpredictability, uncontrollability, and overloading of stress in their lives; scores range from 0-40; higher scores correspond to a higher perceived stress level.

Time frame:
baseline (early pregnancy), end of pregnancy (approx 10 months)
Reported as:
Mean · units on a scale
Stress
units on a scaleYoga (CPC+Y)Comparison (CPC Alone)
Baseline1.8 ± 2.21.3 ± 1.4
End of pregnancy0.33 ± 0.81.3 ± 1.4
SecondaryNumber of Subjects Participating in Focus Group

Women will volunteer to discuss their experiences (acceptability) with the intervention through focus groups conducted following the intervention period

Time frame:
at intervention completion, an average of 20 weeks
Reported as:
Count of participants · Participants
Number of Subjects Participating in Focus Group
ParticipantsYoga (CPC+Y)
Number of Subjects Participating in Focus Group8
SecondaryRecruitment Feasibility

Numbers of women who agreed to participate in the study;

Time frame:
at intervention completion, an average of 20 weeks
Reported as:
Number · participants
Recruitment Feasibility
participantsYoga (CPC+Y)Comparison (CPC Alone)
Recruitment Feasibility1517

Adverse events

Collected over intervention period (9 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Yoga (CPC+Y)0/15 (0%)0/15 (0%)0/15 (0%)
Comparison (CPC Alone)0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Yoga (CPC+Y)Comparison (CPC Alone)Total
Mean29.3 ± 6.524.4 ± 5.626.6 ± 6.4
Sex: Female, Male
Sex: Female, Male(Participants)Yoga (CPC+Y)Comparison (CPC Alone)Total
Female151732
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Yoga (CPC+Y)Comparison (CPC Alone)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7815
White8917
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Yoga (CPC+Y)Comparison (CPC Alone)Total
United States151732
08

Study locations

1 site
  • Virginia Commonwealth University School of Nursing
    Richmond, Virginia 23298, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02873481
Lead sponsor
Virginia Commonwealth University
Collaborators
Sigma Theta Tau International Honor Society of Nursing, Southern Nursing Research Society
Responsible party
Patricia Anne Kinser (Assistant Professor, Virginia Commonwealth University) — Principal investigator
First posted
Aug 19, 2016
Start date
Jul 2015
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Jun 6, 2018
Last update
Jun 6, 2018

Study contacts

Patricia Kinser, PhD
principal investigator · VCU

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion